ArticleCancers2026
A Phantom Investigation of the Robustness and Adaptability of a Novel PET LINAC During Lung Cancer Biology-Guided Radiotherapy (BgRT) Characterized by Unplanned Perturbations in the Tumor Trajectory.
Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This novel biology-guided radiotherapy system (BgRT), the RefleXion X1 SCINTIX™ system, uses annihilation photons produced from a PET-avid tumor to plan and then subsequently guide the delivery of beamlets of radiation to the tumor, tracking the dose delivered in real time. The current BgRT system is cleared by the U.S. Food and Drug Administration (FDA) to treat tumors in the lung or bone characterized by periodic or non-periodic motion, respectively. In this work, we assessed the robustness and adaptability of the dose tracking capability under tumor motion perturbation. We designed a phantom study based on a lung case planned under periodic tracking for four-pass (4-Pass) BgRT and then introduced transient translational shifts to the phantom motion continuously under treatment. By comparing the dose delivered under a normal periodic sinusoidal tumor motion to the dose delivered under a perturbed sinusoidal delivery, with a simple perturbation situation characterized by a perturbation introduced at the end of the second pass of the 4-Pass delivery and a more complex situation with perturbation introduced at each of the four passes of the 4-Pass delivery, we assessed the robustness and adaptability of the RefleXion X1 SCINTIX™ system in delivering the correct dose under such circumstances.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.